Apomorphine Infusion Device Again Before FDA for Approval

Apomorphine Infusion Device Again Before FDA for Approval

313902

Apomorphine Infusion Device Again Before FDA for Approval

Supernus Pharmaceuticals has again applied to the U.S. Food and Drug Administration (FDA) requesting that its apomorphine infusion device (SPN-830), allowing continuous treatment of Parkinson’s disease motor symptoms, be approved. “SPN-830 is an important product candidate which, if approved by the FDA, represents a novel approach for PD [Parkinson’s disease] patients,” Jack Khattar, president and CEO of Supernus, said in a press release. Parkinson’s is characterized by the loss of the nerve cells that produce…

You must be logged in to read/download the full post.